Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07565844

Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia

Led by Zagazig University · Updated on 2026-05-04

45

Participants Needed

1

Research Sites

92 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This randomized controlled clinical trial will evaluate and compare the efficacy and safety of intradermal injection of exosomes, platelet-rich plasma, and corticosteroid in patients with post-herpetic neuralgia. Forty-five adult patients with dermatomal pain persisting for at least 90 days after herpes zoster will be enrolled from outpatient clinics. Participants will be assigned to one of three groups: intradermal exosome injection, intradermal autologous platelet-rich plasma injection, or intradermal triamcinolone acetonide injection. Each group will receive four treatment sessions every two weeks. Outcomes will include pain severity, neuropathic pain characteristics, quality of life, patient satisfaction, and adverse effects, assessed at baseline, at the final session, and during follow-up visits at 3 and 6 months after the last session.

CONDITIONS

Official Title

Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with post-herpes zoster persistent dermatomal pain consistent with post-herpetic neuralgia for at least 90 days
  • Male or female patients aged 18 years or older
  • Willingness to comply with study procedures and attend follow-up visits
  • Ability and willingness to provide written informed consent
Not Eligible

You will not qualify if you...

  • History of hypersensitivity to any of the study treatments
  • Pregnancy
  • Any type of skin infection involving the affected dermatome
  • Immunocompromised patients, including those with cancer or HIV
  • Patients with bone marrow aplasia
  • Patients with known bleeding tendencies, platelet dysfunction, or thrombocytopenia (platelet count less than 150 × 10⁹/L)
  • Regular use of anticoagulant or antiplatelet drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zagazig University Hospitals

Zagazig, Zagazig, Egypt, 44519

Actively Recruiting

Loading map...

Research Team

M

mona Elradi

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here